Icatibant Injection, Solution
Product Images NDC 0093-3066

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Icatibant (NDC 0093-3066). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 1)

Chemical structure diagram of Icatibant showing the detailed molecular composition including peptide bonds, functional groups, and repeating units as part of its chemical formula.*

FDA Label Image

1 (Image 10)

An instructional black-and-white line drawing showing one hand holding a small vial while the other hand uses a syringe to draw solution from the vial. An arrow indicates the direction of syringe insertion into the vial.*

FDA Label Image

1 (Image 11)

An illustration showing a hand holding a syringe with the needle pointing outward. This image depicts the correct hand positioning for administering an injection, likely subcutaneous as related to the product Icatibant injection, solution.*

FDA Label Image

1 (Image 12)

An instructional line drawing showing a hand performing a subcutaneous injection into the abdomen area, illustrating the proper injection site for a medication.*

FDA Label Image

1 (Image 13)

An instructional diagram showing two methods for holding a syringe for subcutaneous injection. The first shows holding the syringe at a 45-degree angle, and the second shows it held at a 90-degree angle, each positioned for injection into the skin.*

FDA Label Image

1 (Image 14)

An instructional illustration showing a hand holding a syringe injecting a solution subcutaneously into the abdomen area of another person. The diagram emphasizes the correct subcutaneous injection technique for administering medication.*

FDA Label Image

1 (Image 15)

An instructional illustration showing a hand holding a syringe injecting a solution subcutaneously into the skin of the abdomen, indicated by an arrow pointing to the injection site.*

FDA Label Image

1 (Image 16)

An instructional illustration showing a hand administering a subcutaneous injection near the abdomen, with an arrow indicating the injection site. This is relevant to Icatibant injection, solution, 10 mg/mL by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

1 (Image 17)

An instructional illustration showing two hands disposing of a used syringe into a sharps biohazard container. The container is labeled with a biohazard symbol and the warnings "DO NOT RECYCLE" and "CONTAINS SHARPS." This diagram emphasizes safe disposal of injection needles.*

FDA Label Image

1 (Image 18)

Icatibant Injection 10 mg/mL (30 mg/3 mL) solution for subcutaneous injection in a single prefilled syringe. The carton label indicates storage instructions, manufacturer details (Teva Pharmaceuticals USA, Inc.), and includes usage warnings. The package contains one prefilled syringe and one 25G hypodermic needle. The NDC is 0093-3066-34.*

FDA Label Image

2 (Image 2)

A Kaplan-Meier survival curve comparing Icatibant and placebo groups in achieving a 50% reduction in symptoms over time up to 60 hours post-dose. The graph shows a faster and higher proportion of patients treated with Icatibant achieving symptom reduction compared to placebo.*

FDA Label Image

1 (Image 3)

An instructional diagram showing components of a prefixed syringe for Icatibant injection, including the syringe barrel, plunger, and protective cap over the syringe tip. Additional illustrations depict a capped needle with needle cap and needle cap seal, and an alcohol wipe, noted to not be included in the carton.*

FDA Label Image

1 (Image 4)

An instructional illustration showing a person's hand removing a protective cover from a prefilled syringe inside its packaging tray. The diagram is related to the injection, solution dosage form of Icatibant, a human prescription drug by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

1 (Image 5)

An instructional line drawing showing two hands holding a vial and a syringe or dropper. One hand holds the vial upright, while the other hand holds the syringe or dropper above it, demonstrating the process of drawing liquid from the vial into the syringe or dropper.*

FDA Label Image

1 (Image 6)

An instructional illustration showing two hands preparing a prefilled syringe for injection. One hand holds the syringe while the other hand removes the protective cap from the needle end, indicated by an arrow pointing outward. A small cap is shown detached below the syringe.*

FDA Label Image

1 (Image 7)

An instructional illustration showing a pair of hands demonstrating how to use a syringe. One hand holds the syringe while the other hand is shown pulling a protective cap off the needle by twisting it, indicating preparation for injection.*

FDA Label Image

1 (Image 8)

An anatomical illustration showing the front view of the lower torso with two shaded squares on the left and right lower abdomen and a droplet shape above centered between the squares, likely indicating recommended sites for subcutaneous injections.*

FDA Label Image

1 (Image 9)

A black and white line drawing illustrating a hand holding a syringe, positioned against the abdomen, demonstrating the subcutaneous injection site typically used for administering the Icatibant injection solution.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.